Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV

MONTREAL, Dec. 06, 2021 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the submission of a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration (FDA) for the Company’s intravenous (IV) push form of administration of Trogarzo®. The IV Push Trogarzo® program continues the Company’s commitment to improving the lives and treatment outcomes for patients living with HIV. Read More